065660.KQ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 liep. 2024 @ 08:10):
Our systems believe the stock currently is undervalued by 0.01% compare to its pairs and should correct upwards.

Stats
Dzisiejszy wolumen	12 415
Średni wolumen	49 707
Kapitalizacja rynkowa	144.90B
EPS	KRW-58.72 ( Q1 \| 2024-03-31 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW22.16 (0.15%)

Korelacja (AI algo v.1.1b): Undervalued: 0.01% KRW14 891 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: 0.27 (neutral)

Krótki: 0.57 (weak)

Signal:(42.019) Neutral

Anterogen.Co.,Ltd. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Anterogen.Co.,Ltd. Korelacja - Waluta/Towar

0.64
( weak )

0.51
( weak )

0.24
( neutral )

-0.24
( neutral )

-0.40
( neutral )

0.48
( neutral )

Anterogen.Co.,Ltd. Finanse

Annual	2023
Przychody:	KRW6.50B
Zysk brutto:	KRW2.21B (34.05 %)
EPS:	KRW-291.93

FY	2023
Przychody:	KRW6.50B
Zysk brutto:	KRW2.21B (34.05 %)
EPS:	KRW-291.93

FY	2022
Przychody:	KRW6.59B
Zysk brutto:	KRW2.62B (39.70 %)
EPS:	KRW-705.88

Financial Reports:

No articles found.

Anterogen.Co.,Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.